

p53 siRNA (h2): sc-44218

BACKGROUND

p53, a DNA-binding, oligomerization domain- and transcription activation domain-containing tumor suppressor, upregulates growth arrest and apoptosis-related genes in response to stress signals, thereby influencing programmed cell death, cell differentiation, and cell cycle control mechanisms. p53 localizes to the nucleus, yet can be chaperoned to the cytoplasm by the negative regulator, MDM2. MDM2 is an E3 ubiquitin ligase that is upregulated in the presence of active p53, where it poly-ubiquitinates p53 for proteasome targeting. p53 fluctuates between latent and active DNA-binding conformations and is differentially activated through posttranslational modifications, including phosphorylation and acetylation. Mutations in the DNA-binding domain (DBD) of p53, amino acids 110-286, can compromise energetically-favorable association with *cis* elements and are implicated in several human cancers.

CHROMOSOMAL LOCATION

Genetic locus: TP53 (human) mapping to 17p13.1.

PRODUCT

p53 siRNA (h2) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see p53 shRNA Plasmid (h2): sc-44218-SH and p53 shRNA (h2) Lentiviral Particles: sc-44218-V as alternate gene silencing products.

For independent verification of p53 (h2) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-44218A, sc-44218B and sc-44218C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

p53 siRNA (h2) is recommended for the inhibition of p53 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

p53 (DO-1): sc-126 is recommended as a control antibody for monitoring of p53 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor p53 gene expression knockdown using RT-PCR Primer: p53 (h2)-PR: sc-44218-PR (20 μ l, 537 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

SELECT PRODUCT CITATIONS

- Shetty, S., et al. 2007. Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA. *Mol. Cell. Biol.* 27: 5607-5618.
- Jalili, A., et al. 2011. Polo-like kinase 1 is a potential therapeutic target in human melanoma. *J. Invest. Dermatol.* 131: 886-895.
- Pathria, G., et al. 2012. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. *J. Invest. Dermatol.* 132: 2780-2790.
- Saha, K., et al. 2014. p38 δ regulates p53 to control p21^{Cip1} expression in human epidermal keratinocytes. *J. Biol. Chem.* 289: 11443-11453.
- Hung, N., et al. 2014. Increased paired box transcription factor 8 has a survival function in glioma. *BMC Cancer* 14: 159.
- Yao, Z., et al. 2016. The effect of epigenetic silencing and TP53 mutation on the expression of DLL4 in human cancer stem disorder. *Oncotarget* 7: 62976-62988.
- Chen, J., et al. 2017. DNA damage induces expression of WWP1 to target Δ Np63 α to degradation. *PLoS ONE* 12: e0176142.
- Gao, P., et al. 2018. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells. *Breast Cancer Res.* 20: 112.
- Shrestha, S., et al. 2020. ACTL6A suppresses p21^{Cip1} expression to enhance the epidermal squamous cell carcinoma phenotype. *Oncogene* 39: 5855-5866.
- Zhang, Z., et al. 2020. The BRD7-p53-SLC25A28 axis regulates ferroptosis in hepatic stellate cells. *Redox Biol.* 36: 101619.
- Tan, X., et al. 2020. Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer. *Cell Death Dis.* 11: 1061.
- Shrestha, S., et al. 2021. ACTL6A suppresses p21^{Cip1} tumor suppressor expression to maintain an aggressive mesothelioma cancer cell phenotype. *Oncogenesis* 10: 70.

RESEARCH USE

For research use only, not for use in diagnostic procedures.